SCHEMBL9130636

SCHEMBL9130636

CN(C)CC/C=C1/c2cc(Br)ccc2COc2ccc(Br)cc21

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 3/20 0.69
HRH1 P35367 4/20 0.63
KCNH2 Q12809 2/20 0.63
ALDH1A1 P00352 2/20 0.63
LMNA P02545 2/20 0.63
SLC22A1 O15245 1/20 0.63
CHRM2 P08172 1/20 0.63
CHRM4 P08173 1/20 0.63
HTR1A P08908 1/20 0.63
CHRM5 P08912 1/20 0.63
ADRA2A P08913 1/20 0.63
CHRM1 P11229 1/20 0.63
DRD2 P14416 1/20 0.63
ADRA2B P18089 1/20 0.63
ADRA2C P18825 1/20 0.63
CHRM3 P20309 1/20 0.63
DRD1 P21728 1/20 0.63
DRD4 P21917 1/20 0.63
DRD5 P21918 1/20 0.63
SLC6A2 P23975 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9130177 1.00 HTR2B (0.69) HTR2BHRH1KCNH2ALDH1A1LMNA
SCHEMBL9129522 1.00 HTR2B (0.69) HTR2BHRH1KCNH2ALDH1A1LMNA
SCHEMBL10345076 0.93 HTR2B (0.81) HTR2BHRH1KCNH2ALDH1A1LMNA
SCHEMBL10344955 0.93 HTR2B (0.81) HTR2BHRH1KCNH2ALDH1A1LMNA
SCHEMBL10344954 0.93 HTR2B (0.81) HTR2BHRH1KCNH2ALDH1A1LMNA
SCHEMBL9128490 0.92 HTR2B (0.83) HTR2BHRH1KCNH2ALDH1A1LMNA
Hydrochloric Acid SCHEMBL9133126 0.92 HTR2B (0.79) HTR2BHRH1KCNH2ALDH1A1LMNA
Hydrochloric Acid SCHEMBL9133130 0.92 HTR2B (0.79) HTR2BHRH1KCNH2ALDH1A1LMNA
SCHEMBL9128498 0.92 HTR2B (0.83) HTR2BHRH1KCNH2ALDH1A1LMNA
SCHEMBL2615561 0.85 HTR2B (0.69) HTR2BHRH1KCNH2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5395610-A Agents for potentiating the effects of antitumor agents and combating multiple drug resistance BURROUGHS-WELLCOME CO. (US) 1995-03-07 US disclosed
US-5300282-A Agents for potentiating the effects of antitumor agents and combating multiple drug resistance BURROUGHS-WELLCOME COMPANY (US) 1994-04-05 US disclosed
EP-0409406-B1 ARYL-SUBSTITUTED AMINE DERIVATIVES USEFUL IN CANCER THERAPY THE WELLCOME FOUNDATION LIMITED (GB) 1993-09-08 EP disclosed
EP-0487502-A2 Pharmaceutically active aryl-substituted amine derivatives THE WELLCOME FOUNDATION LIMITED (GB) 1992-05-27 EP disclosed
EP-0409406-A2 Aryl-substituted amine derivatives useful in cancer therapy THE WELLCOME FOUNDATION LIMITED (GB) 1991-01-23 EP disclosed
WO-1990015599-A1 MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES THE WELLCOME FOUNDATION LIMITED (GB) 1990-12-27 WO disclosed